The present invention relates generally to immunotherapy, in particular immunotherapy for treating cancer, infectious diseases or autoimmune diseases. […]

The present invention relates to methods for predicting the survival time of patients suffering from a lung cancer. In particular, the present […]

The MYC and NMYC transcription factors (TFs) play a key role in cell proliferation and are overexpressed in most cancer cells. However, in normal […]

Monitoring active disease or progressive disease under therapy in chronic lymphocytic leukemia (CLL) represents a challenge to earlier and better […]

The present invention relates to the treatment of cancer. Here, the inventors evaluated EAPB02303 effects in PDAC cell lines and mouse models and […]

Immunotherapy has transformed cancer treatment but often struggles with solid tumors due to immune resistance from the tumor microenvironment (TME). […]

Melanoma cell plasticity plays a key role in the acquisition of resistance to therapy. TRIM24/TIF1α, which encodes for the tripartite […]

The Inventors herein demonstrate that CD39 is a relevant therapeutic target in B-celllymphoma, in particular Follicular Lymphoma (FL), Diffuse Large […]

The cholangiocarcinoma cell line SB1-JP4 is syngeneic to C57Bl/6 mice.It was derived from a tumor formed by SB1 cells in C57Bl/6 mice, then harvested, […]

PTLDs arise after solid organ and hematopoietic stem cell transplants, with occurrences linked to immunosuppressive therapy and EBV status. Initial […]